Comment on ‘The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment’
British Journal of Clinical Pharmacology · 11.11.2026
DOI: 10.1002/bcp.70920 ↗Kurz gefasst
Leserbrief in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 11.11.2026. Verfasst von Wenxiang Zhang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Thoracic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
ORCID-Profile: Baorui Ren
Zitieren
APA
Zhang, W., & Ren, B. (2026). Comment on ‘The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment’. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70920
Vancouver
Zhang W, Ren B. Comment on ‘The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment’. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70920
BibTeX
@article{Zhang2026,
author = {Zhang, Wenxiang and Ren, Baorui},
title = {Comment on ‘The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment’},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70920}
}
EUVIMED